Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.39B P/E - EPS this Y -1.80% Ern Qtrly Grth -
Income -322.83M Forward P/E -3.32 EPS next Y -10.60% 50D Avg Chg -4.00%
Sales 35.21M PEG 0.03 EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 1.57 EPS next 5Y -97.20% 52W High Chg -65.00%
Recommedations 1.60 Quick Ratio 15.28 Shares Outstanding 162.46M 52W Low Chg 18.00%
Insider Own 1.76% ROA -26.91% Shares Float 101.56M Beta 1.64
Inst Own 80.14% ROE -43.28% Shares Shorted/Prior 9.92M/9.05M Price 11.44
Gross Margin - Profit Margin - Avg. Volume 1,222,646 Target Price 22.30
Oper. Margin -1,060.46% Earnings Date Oct 31 Volume 717,987 Change -3.95%
About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics, Inc. News
11/20/24 Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
11/19/24 Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
11/07/24 Relay Therapeutics to Participate in Upcoming Investor Conferences
11/06/24 Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
10/30/24 Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
10/28/24 Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses
09/17/24 Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?
09/11/24 Why Relay Therapeutics Plummeted by Nearly 14% Today
09/10/24 Relay Therapeutics Announces Pricing of Public Offering of Common Stock
09/10/24 Relay Stock Soars on Upbeat Data From Breast Cancer Study
09/09/24 Relay Therapeutics Announces Proposed Public Offering of Common Stock
09/09/24 Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
09/09/24 Relay breast cancer drug shows potential in early trial
09/09/24 Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
09/06/24 Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
08/06/24 Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
07/30/24 Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
07/24/24 We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
07/17/24 Caribou lays off staff; Roche walks away from Relay
06/06/24 Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
RLAY Chatroom

User Image I_saw_the_kraken Posted - 2 hours ago

$RLAY hold. I will buy 10k shares today. https://finance.yahoo.com/news/down-27-93-4-weeks-143506725.html

User Image Stocksrunner Posted - 18 hours ago

APH flashed a golden cross, BDSX and RLAY look ripe for reversals, while CNK and HLX hit key highs. Big moves ahead? $APH $BDSX $RLAY $CNK $HLX https://stocksrunner.com/posts/1404

User Image Dahlcr Posted - 22 hours ago

$RLAY Raymond James just took it off their best idea list. I have a feeling they will reduce their rating and lower their price target.

User Image Breck100 Posted - 1 day ago

$RLAY do I hold this? I'm in over $6. ;(

User Image GXD_Texas Posted - 1 day ago

$RLAY everyday a new 52 week low. Amazeballs

User Image GXD_Texas Posted - 2 days ago

$RLAY boy. If bad days this is going to penny land. 😑

User Image itsasurewin Posted - 4 days ago

$RKDA $RLAY $RLFTF $RKLB $CERO

User Image Breck100 Posted - 5 days ago

$RLAY why the drop here?

User Image GXD_Texas Posted - 6 days ago

$RLAY wow. Guess our data isn’t compelling

User Image LabPsycho Posted - 6 days ago

$RLAY IMO this thing should drift below $3.95 in a few weeks. IMO, Diluting on the way down when a company has hundreds of millions of cash suggests to me A.I. is just a buzz word that may not be working in house.

User Image GXD_Texas Posted - 6 days ago

$RLAY new 52 week low yay

User Image GXD_Texas Posted - 1 week ago

$RLAY HookEm’🤘🏼

User Image krishkk Posted - 1 week ago

$RLAY lets push to $7 to bring back some attention

User Image Ohzipit Posted - 2 weeks ago

$RLAY RJ post earnings update. Remain strong buy Price target $29.

User Image GXD_Texas Posted - 2 weeks ago

$RLAY plenty of money, filing for phase 3 1st quarter. More data this year. Multiple trials starting this year. $850 million in runway. Through end of 2027. Nice.

User Image GXD_Texas Posted - 2 weeks ago

$RLAY earnings after close. @Ohzipit @valueforme @BigFella2021 @Kingjake26

User Image Breck100 Posted - 2 weeks ago

$RLAY what am i doing with this pos / ER Weds

User Image LabPsycho Posted - 10/31/24

$RLAY In my opinion, one criterion I used to determine if a companys management earns my coveted BioGrifter(TM) alert is a company has hundreds of millions of cash then does a dilution near all time lows, after of course previously using the term cash runway implying no dilution in the near future. Big dilutions on the way down suggests to me something aint working right and the A.I. might just be a buzz word tossed in for fun. I can think of several companies this may apply to. Good luck

User Image GXD_Texas Posted - 10/31/24

$RLAY new 52 week low. 😖

User Image insiderbuyingselling Posted - 10/31/24

$RLAY new insider selling: 1632 shares. http://insiderbuyingselling.com/?t=RLAY

User Image ECHorizon Posted - 10/30/24

$RLAY ER on 11/6 after-hours. https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announce-third-quarter-2024-financial-results

User Image insiderbuyingselling Posted - 10/30/24

$RLAY new insider selling: 1621 shares. http://insiderbuyingselling.com/?t=RLAY

User Image krishkk Posted - 10/29/24

$RLAY this going along with market red.. hope it will recover soon not break the stop loss..

User Image Breck100 Posted - 10/29/24

$RLAY any thoughts here? seems super volatile but has $16-$28 target

User Image GXD_Texas Posted - 10/25/24

$RLAY we suck again hahahah still

User Image Awiz2 Posted - 1 month ago

$RLAY News will make this quadruple when it hits!

User Image Oldgrape Posted - 1 month ago

$RLAY they are looking for a global commercialisation partner for RLY-4008 targeting FGFR2 in Solid tumours. Probably waiting for FDA nod to file NDA in CCA They also have an abstract submitted for ENA 2024

User Image Oldgrape Posted - 1 month ago

$RLAY someone decided to close their December $5 puts

User Image Ohzipit Posted - 1 month ago

$RLAY from RJ 10/2

User Image yus37 Posted - 1 month ago

$BCTX I've added more to my position because I believe in what the company is doing to fight cancer... With the current market cap, it looks like a good risk vs reward.... I think it could reach a $400-500 million market cap... Just my opinion, as I'm biased and now hold 3,500 shares. Not financial advice... $IOVA $SMMT $RLAY $XBI

Analyst Ratings
JMP Securities Market Outperform Sep 17, 24
Stifel Buy Sep 16, 24
HC Wainwright & Co. Buy Sep 16, 24
B of A Securities Buy Sep 10, 24
JP Morgan Overweight Sep 10, 24
Barclays Overweight Sep 10, 24
Jefferies Buy Sep 10, 24
Oppenheimer Perform Sep 10, 24
JP Morgan Overweight Aug 7, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rahmer Peter See remarks See remarks Jan 29 Sell 9.64 1,651 15,916 514,977 01/31/24
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Jan 29 Sell 9.64 2,005 19,328 341,846 01/31/24
Bergstrom Donald A President, R&D President, R&D Jan 29 Sell 9.64 3,178 30,636 530,878 01/31/24
Rahmer Peter See remarks See remarks Dec 27 Sell 11.51 244 2,808 316,628 12/29/23
Bergstrom Donald A President, R&D President, R&D Oct 30 Sell 6.03 3,451 20,810 235,033 11/01/23
Adams Brian Chief Legal Officer Chief Legal Officer Oct 30 Sell 6.03 1,632 9,841 129,961 11/01/23
Bergstrom Donald A President, R&D President, R&D Sep 27 Sell 8.38 648 5,430 238,484 09/29/23
Rahmer Peter See remarks See remarks Sep 27 Sell 8.38 244 2,045 318,226 09/29/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Sep 27 Sell 8.38 294 2,464 145,842 09/29/23
Rahmer Peter See remarks See remarks Jul 28 Sell 11.80 1,352 15,954 316,808 07/31/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Jul 28 Sell 11.80 1,693 19,977 146,136 07/31/23
Rahmer Peter See remarks See remarks Apr 28 Sell 11.16 1,657 18,492 156,586 06/01/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Apr 28 Sell 11.16 863 9,631 149,272 05/01/23
Rahmer Peter See remarks See remarks Mar 27 Sell 15.36 297 4,562 158,243 03/28/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Mar 27 Sell 15.36 347 5,330 150,135 03/28/23
Bergstrom Donald A President, R&D President, R&D Mar 27 Sell 15.36 763 11,720 244,084 03/28/23
Adams Brian Chief Legal Officer Chief Legal Officer Mar 27 Sell 15.36 347 5,330 135,745 03/28/23
Patel Sanjiv President and CEO President and CEO Jan 17 Sell 20.37 84,000 1,711,080 254,554 01/19/23
Patel Sanjiv President and CEO President and CEO Jan 17 Option 5.04 84,000 423,360 282,554 01/19/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Dec 27 Sell 14.49 445 6,448 50,231 12/28/22
Porter Andy Chief Administrative.. Chief Administrative Officer Sep 27 Sell 22.73 259 5,887 45,612 09/29/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Sep 27 Sell 22.73 443 10,069 51,775 09/29/22
Bergstrom Donald A President, R&D President, R&D Sep 27 Sell 22.73 976 22,184 88,683 09/29/22
Adams Brian Chief Legal Officer Chief Legal Officer Sep 27 Sell 22.73 294 6,683 62,548 09/29/22
Patel Sanjiv President and CEO President and CEO Sep 13 Sell 24.24 42,000 1,018,080 254,554 09/15/22
Patel Sanjiv President and CEO President and CEO Sep 13 Option 4.12 42,000 173,040 268,554 09/15/22
Murcko Mark Director Director Sep 08 Sell 29.95 25,000 748,750 996,952 09/08/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Sep 08 Option 4.12 26,257 108,179 78,475 09/08/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Sep 08 Sell 30 26,257 787,710 52,218 09/08/22
Bergstrom Donald A President, R&D President, R&D Sep 08 Option 4.12 25,000 103,000 114,659 09/08/22
Bergstrom Donald A President, R&D President, R&D Sep 08 Sell 30 25,000 750,000 89,659 09/08/22
Bergstrom Donald A President, R&D President, R&D Sep 02 Option 4.12 4,900 20,188 94,559 09/02/22
Bergstrom Donald A President, R&D President, R&D Sep 02 Sell 25.46 4,900 124,754 89,659 09/02/22
Bergstrom Donald A President, R&D President, R&D Sep 01 Option 4.12 8,100 33,372 97,759 09/01/22
Bergstrom Donald A President, R&D President, R&D Sep 01 Sell 23.07 8,100 186,867 89,659 09/01/22
Bergstrom Donald A President, R&D President, R&D Aug 24 Option 4.12 15,000 61,800 104,659 08/25/22
Bergstrom Donald A President, R&D President, R&D Aug 24 Sell 25 15,000 375,000 89,659 08/25/22
Bergstrom Donald A President, R&D President, R&D Aug 05 Option 4.12 8,000 32,960 97,659 08/08/22
Bergstrom Donald A President, R&D President, R&D Aug 05 Sell 20 8,000 160,000 89,659 08/08/22
Porter Andy Chief Administrative.. Chief Administrative Officer Jul 28 Sell 21.27 452 9,614 45,871 07/29/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Jul 28 Sell 21.26 734 15,605 52,218 07/29/22
Bergstrom Donald A President, R&D President, R&D Jul 28 Sell 21.27 1,835 39,030 89,659 07/29/22
Bergstrom Donald A President, R&D President, R&D Jul 06 Option 4.12 8,000 32,960 99,494 07/08/22
Bergstrom Donald A President, R&D President, R&D Jul 06 Sell 20 8,000 160,000 91,494 07/08/22
Porter Andy Chief Administrative.. Chief Administrative Officer Jun 27 Sell 20.31 265 5,382 46,323 06/28/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Jun 27 Sell 20.31 300 6,093 52,952 06/28/22
Adams Brian Chief Legal Officer Chief Legal Officer Jun 27 Sell 20.31 300 6,093 63,576 06/28/22
Bergstrom Donald A President, R&D President, R&D Jun 24 Option 4.12 8,000 32,960 100,493 06/28/22
Bergstrom Donald A President, R&D President, R&D Jun 24 Sell 20.16 8,999 181,420 91,494 06/28/22
Bergstrom Donald A President, R&D President, R&D Apr 28 Option 4.12 13,000 53,560 105,493 05/02/22